McKesson Corporation Oncology & Multispecialty revenue
Oncology & Multispecialty revenue at McKesson Corporation came to $15.0B for the quarter to 30 Sep 2026, up 24.4% from a year earlier.
As McKesson Corporation reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 4 Nov 2026.
By quarter
| Period ending | Oncology & Multispecialty revenue | Change on a year | Filed |
|---|---|---|---|
| 30 Sep 2026 | $15.0B | up 24.4% | 4 Nov 2026 |
| 30 Jun 2026 | $14.2B | up 33.4% | 5 Aug 2026 |
| 31 Mar 2026 | $12.7B | — | 8 May 2026 |
| 31 Dec 2025 | $13.0B | up 37.0% | 4 Feb 2026 |
| 30 Sep 2025 | $12.0B | up 31.5% | 6 Nov 2025 |
| 30 Jun 2025 | $10.7B | — | 6 Aug 2025 |
| 31 Dec 2024 | $9.5B | — | 6 Feb 2025 |
| 30 Sep 2024 | $9.2B | — | 7 Nov 2024 |
Definition
Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.
Other operating KPIs of McKesson Corporation: North American Pharmaceutical revenue · Medical-Surgical Solutions revenue · Prescription Technology Solutions revenue · financial statements
Every KPI and segment of MCK, in the terminal.
Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.
